Here’s the thing about Eli Lilly right now. The stock ran nearly 10% on a single earnings day, Q1 revenue came in at $19.8 billion — a 56% year-over-year surge — and the Street is still arguing about valuation. Meanwhile, the options market has been quietly pricing something much larger than a quarterly beat.
The numbers first.
Lilly’s Q1 2026 non-GAAP EPS printed at $8.55, up 156% from the year-ago period. Full-year revenue guidance was raised to $80–$83 billion against a Street consensus of $77.6 billion. That’s not a modest beat — it’s a structural reset. The company’s U.S. GLP-1 market share climbed to 60.5% in Q4 2025, up 2.6 points from the prior quarter, while rival Novo Nordisk simultaneously warned that 2026 sales and profits could decline by as much as 13%. One company is pulling away. The other is defending. That dynamic rarely reverses quickly.
Slight tangent, but it matters: the orforglipron catalyst is sitting in the background and barely getting priced in. Lilly has guided to global regulatory submissions for obesity following positive Phase 3 readouts on what would be the company’s first oral GLP-1 — no injection, no cold chain. If that product clears FDA, the total addressable market doesn’t expand incrementally. It expands categorically.
What the Tape Is Doing
LLY was trading around $1,064 heading into the Memorial Day holiday weekend, with a 52-week range of $623.78 to $1,133.95. The stock is still roughly 6% off its all-time high — which, given the fundamental gap between Q1 reality and year-ago expectations, is an interesting setup. Volume on May 25 came in at 3.47 million shares against an average daily volume of 2.96 million. Above-average participation on a pre-holiday Friday is not nothing.
On the options side, LLY’s 30-day implied volatility has been elevated relative to its historical baseline, a pattern that tends to persist in names with active pipeline catalysts. IV rank is a key variable here — when IV is elevated but not at peak, premium sellers and defined-risk spread buyers often find the most symmetrical setups. The term structure warrants watching: a contango shape (IV rising at longer expirations) signals the market is expecting sustained uncertainty, not just a short event window.
Trade Framework
Bull case: For traders expecting continued GLP-1 volume growth and orforglipron progress, a defined-risk bull call spread targeting the $1,100–$1,150 range into Q3 would express upside while limiting premium outlay in a still-elevated IV environment. A July or August expiration gives time for the next pipeline data point to emerge.
Bear case: If you believe pricing pressure, Medicare negotiation risk, or a Novo Nordisk recovery could compress Lilly’s multiple, a put spread in the $950–$900 range with a 60–90 day window offers a defined-risk short thesis. The 27.5x NTM earnings multiple leaves room for derating if the narrative shifts.
Neutral / income case: Given the stock’s proximity to its 52-week high and elevated IV, a covered call or short strangle structure targeting the $1,050–$1,100 zone could harvest premium in a sideways-to-slightly-higher tape.
Risk Factors
- Medicare drug price negotiation timelines could accelerate pressure on GLP-1 pricing
- Competitive pipeline from Novo Nordisk and emerging biotech names remains active
- Manufacturing scale-up risk if demand outpaces capacity
- Geopolitical exposure — supply chain diversification is ongoing but not complete
The part people skip: LLY’s full-year EPS guidance of $33.50–$35.00 is above the $33.04 consensus, and performance margin is expected between 46% and 47.5%. That’s not a pharma margin profile. That’s a software margin profile on a drug franchise. The market is paying for it. The question is whether the next 12 months prove the valuation right — or reveal that expectations are already running ahead of reality.
Watch the orforglipron regulatory timeline closely. That’s the asymmetric variable the consensus is underpricing.
